Genflow Biosciences to hold AGM on 29 June 2026

GENF

Genflow Biosciences Plc (LON:GENF)(OTCQB:GENFF), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, has announced that it will hold its Annual General Meeting (AGM) at 11am on Monday 29 June 2026 at One Heddon Street, London, W1B 4BD.

The Notice of the AGM and Form of Proxy will shortly be available on the Company’s website, www.genflowbio.com, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year’s AGM are set out in the Notice.

As announced on 30 April 2026, the Company’s Annual Report and Accounts for the year ended 31 December 2025 are also available on the website and have, where applicable, also been posted to shareholders.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Genflow Biosciences moves longevity programme towards its next test

Genflow Biosciences has reported better survival rates and no adverse events three months into its ageing-dog gene therapy study.

Genflow Biosciences advances a focused gene therapy pipeline for healthy ageing

Genflow Biosciences is building a focused SIRT6 gene therapy pipeline across human health, veterinary medicine and skin-related applications.

SIRT6 positions Genflow Biosciences in a high-value area of longevity research

Genflow Biosciences is targeting SIRT6 as a potential route to improve DNA repair, metabolic control and healthier ageing.

Genflow Biosciences reports continued SIRT6 progress in first half of 2026

Genflow Biosciences reported positive interim and three-month follow-up results from its SLAB canine trial, expanded animal health partnerships, secured a fully funded LNP collaboration with Acuitas Therapeutics and strengthened its SIRT6 patent portfolio.

Gene research sharpens the case for targeted biotechnology

Genflow’s focus on SIRT6 highlights how gene science is shaping more targeted approaches to ageing and age-related disease.

Genflow Biosciences prepares for key longevity data

Genflow Biosciences is set to present full dog longevity study results that could shape its animal health strategy and partnership prospects.

Search